5-carbamoyl-1h-imidazol-4-yl-piperonylate has been researched along with Leukemia P388 in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fukui, M; Inaba, M; Sakurai, Y; Tsukagoshi, S; Yoshida, N | 1 |
Atsumi, T; Fukui, M; Inaba, M; Kiyohara, T; Ogino, S; Sakurai, Y; Tsukagoshi, S; Yoshida, N | 1 |
Fukui, M; Inaba, M; Sakurai, Y; Tsukagoshi, S | 1 |
3 other study(ies) available for 5-carbamoyl-1h-imidazol-4-yl-piperonylate and Leukemia P388
Article | Year |
---|---|
Collateral sensitivity of 6-mercaptopurine-resistant sublines of P388 and L1210 leukemia to the new purine antagonists, 5-carbamoyl-1H-imidazol-4-yl piperonylate and 4-carbamoylimidazolium 5-olate.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Guanosine Monophosphate; Hypoxanthine Phosphoribosyltransferase; Imidazoles; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Mercaptopurine; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Purines | 1982 |
Antitumor activities of newly synthesized 5-carbamoyl-1 H-imidazol-4yl 1-adamantanecarboxylate and 5-carbamoyl-1H-imidazol-4yl piperonylate.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Imidazoles; Injections, Intraperitoneal; Leukemia P388; Life Expectancy; Lung Neoplasms; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Prognosis | 1980 |
Selective reduction of intracellular guanosine 5'-triphosphate pool by 4-carbamoylimidazolium 5-olate in murine tumor cells.
Topics: Adenine Phosphoribosyltransferase; Animals; Carcinoma, Ehrlich Tumor; Cell Line; Drug Resistance; Guanosine Triphosphate; Imidazoles; IMP Dehydrogenase; Leukemia P388; Mice; Neoplasms, Experimental | 1986 |